Renew treatment are undifferentiated cells with the capacity to differentiate into functional cells and with the capacity for self-renewal. According to their origin, they can be classified into embryonic & adult Renew treatment.
Adult Renew treatment have been identified in many organs and tissues, including brain, bone marrow, peripheral blood, blood vessels, skeletal muscle, skin, fat, teeth, heart, intestine, liver, ovarian epithelium, and testicles.
They are believed to reside in a specific area of each tissue (called a“stem cell niche”). We will refer to those obtained from bone marrow and fat, which are the most common extraction sites for cell therapy.
It has been shown that these cells have the ability to differentiate into cells of the 3 embionary tissues mentioned above (ecto-derm, mesoderm and endoderm). The density of these cells in fat is much higher than that of the MSC in bone marrow (100 to 500 times higher).Thus, we understand that ADSCs and SVF represent an autologous (the patient’s own) alternative to pluripotent em-bryonic Renew® treatment with multi-line transformation potential, significant therapeutic impact and a critical role in the field of tissue engineering and Innovative medicine.However, its incredible properties do not end there, much of its clinical importance is due to its secretory and immunomodulators functions.
Similar to the original adipose tissue from which they can be isolated, ADSCs have been shown to act as a “secretoma”, accurately regulating the proteins and growth factors secreted in the extracellular medium and having a relevant impact on different organs and systems within the human body.The trophic effects of ADSCs include stimulation of blood vessel formation, blood cells, gene transfer, and suppression of inflammation. In fact, ADSCs represent a source of several growth factors and cytokines that regulate the survival and differentiation of various cells and tissues.A large number of these molecules have been related to the innovative capacity of the ADSCs. It is not the purpose of this post to list all the cytokines that have already been isolated, so we limit ourselves to mention afew in the attached table.In conclusion, most of the factors secreted from ADSC act through mechanisms that mediate protection against cell death or, alternatively, induce cell migration and proliferation.In addition, they can act indirectly on target cells by promoting vascularization, with the consequent increase in oxygen and nutrient transport in affected areas, which in turn can promote local innovative processes.
The immunomodulatory properties of ADSC and MSC have attracted interest as a unique property of these cells that can and should, we think, be harnessed for novel therapeutic approaches in autoimmune diseases.Mesenchymal Renew® treatment have been shown to inhibit the proliferation of both in vitro and in vivo activated T cells, but they stimulate the proliferation of regulatory T cells.Mesenchymal Renew® treatment are also known to be weakly immunogenic and to exert immunosuppressive effects on B cells, Natural killer cells, dendritic cells and neutrophils through various mechanisms.In addition, intravenous administration of allogeneic mesenchymal Renew® treatment has shown a marked suppression of host immune reactions in animal models of organ transplant rejection and in various autoimmune and inflammatory diseases.Some clinical trials using human mesenchymal Renew® treatment have also produced promising results in patients with graft-versus-host disease and autoimmune diseases.
Dr. Luque is a prestigios specialist with more than 20 years of experience in regenarative & aesthetic medicine.She is an expert in Renew treatment derived from fat. Outstanding curriculum in medicine & research ‘Cum Laude’ by the University of Malaga & in Sweden.